TagyouRit
Posted - 1 minute ago
$ESPR added 2300 shares @2bucks. Still believe they need professional sales force to bolster their sales teams.
Dave_100
Posted - 1 minute ago
@djohnson591 The collaboration revenue $ESPR recognizes includes royalties and sales of bulk pills. This means while will save costs on production moving to DSE there will be revenue they are giving up as well. I dont know the pricing they use one the bulk sales but assume they would not be selling below cost.
YoloAlfred
Posted - 2 minutes ago
$ESPR Take a look at DOW & NASDAQ
tkstockpicker
Posted - 2 minutes ago
$ESPR This POS is just pure fun
theDeathStar
Posted - 12 minutes ago
$ESPR biotech is a sea of red today.
BullDonald
Posted - 15 minutes ago
$ESPR I dont have to add any thing, abecause i fear if i keep adding all the lows, i may end up owning the company one day🥴
Handyman72
Posted - 18 minutes ago
$ESPR budding on 50 more jun 2 calls gregg!! ;)
LeftyT
Posted - 20 minutes ago
@Masterjerm Added 10% to my $ESPR position. Great international numbers by DSE last night set the stage for big growth in USA to be reported in a couple weeks.
LeftyT
Posted - 24 minutes ago
$ESPR I'm adding at 1.99 with a smile!
ACstranger
Posted - 27 minutes ago
$ESPR buy all you can imo!
ejz92
Posted - 27 minutes ago
$ESPR 10 year over 4.70
ACstranger
Posted - 28 minutes ago
$ESPR the fickers can do whatever they want. A probability of 95% that this company will be a big pharma with a marketcap of 30-80 billion. That unless a buyout or fraud of management. Seems unlikely.
tkstockpicker
Posted - 31 minutes ago
$ESPR back in at 2.02
johnmchugh
Posted - 32 minutes ago
$ESPR Whenever there is positive action overnight the shorts hit hard the following morning. Interesting manipulation pattern. Buyers keep your trades small and regular if you want to see a steady increase in market valuation!
HardLessons
Posted - 33 minutes ago
$ESPR time to buy now, green by EOD
NumberWang
Posted - 34 minutes ago
$ESPR inflation up, GDP down; for any company loaded with debt this is bad news as chances of re-fi are ~ 0. Now all hinges in sales in the US honestly. EU/UK this company is knee-capped. Shelly better show real progress in US sales ramp-up. Otherwise it's going to be painful, regardless of sales abroad.
sogenerous
Posted - 34 minutes ago
$ESPR Rejected at key 2.16 lvl yesterday , now back down despite DSE sales shoping some lift. Better to wait for clarity post earnings to see what shelby has in store
tkstockpicker
Posted - 37 minutes ago
$ESPR stopped at open and took my gain
Sushiman12345
Posted - 37 minutes ago
$ESPR Market don't give a fuck about the daiichi sales lol, they are like fuck u bro! Time to sell off! We needed their sales to be 10X each quarter instead of 2X
Dobbins
Posted - 40 minutes ago
$ESPR getting some 2.04s long
tjguy
Posted - 41 minutes ago
$ESPR Market does not seem excited about the DSE sales figures it seems.
djohnson591
Posted - 42 minutes ago
$ESPR Remember the cost saving and sales build up from the DSE settlement and script bridge program will really hit end of 2024 and beginning of 2025.
Dobbins
Posted - 43 minutes ago
$ESPR stupid no reason to sell this. The value is only going up. Will buy the dip if they dip her.
theDeathStar
Posted - 50 minutes ago
$ESPR a 44% capital gains tax and a 25% unrealized gains tax is insane. Not even a Biden voter can be dumb enough to think that those proposals are a good idea much less actually work.
Borattotherescue
Posted - 57 minutes ago
$ESPR with expended label/growth CF+ is on the horizon. 2025. Just my 2 cents
djohnson591
Posted - 1 hour ago
$ESPR DSE sales were great (as usual). I do think a few things affected DSE Q4-23 sales. The end of litigation with ESPR occurred in this quarter, along with rumbling from Europe that samples were running out or low (I'm assuming that's why they're so eager to get the new DSE facility up and running, along with Neuland Labs expanded production within the next few weeks). These numbers should really start to explode with a Primary Prevention label in the EU (if that occurs). What's odd is DS estimates $232m in BA sales for 2024, yet their 5 year plan shows BA sales being equivalent to their Tarlige sales in 2024 (which they forecast will be around $350m). I see some sandbagging going on. FYI - I've attached my estimates below (these are just my estimates and should be taken with a grain of salt). I changed it to EUR instead of JPY (easier to read and understand). I do think by 2027 BA with a Primary Prevention label will have sales that land somewhere between Zetia and Lipitor.
TomMac64
Posted - 1 hour ago
$ESPR Where is the guy who said interest rates don’t matter ?
TomMac64
Posted - 1 hour ago
$ESPR I believe these numbers are fixed and maybe influenced by all these illegal immigrants ?
TomMac64
Posted - 1 hour ago
$ESPR